Your browser doesn't support javascript.
loading
To stage or not to stage: determining the true clinical significance of the biopsy tract through perinephric fat in assessing renal cell carcinoma.
Valencia-Guerrero, Aida; Oliva, Esther; Wu, Chin-Lee; Wu, Shulin; Rice-Stitt, Travis; Sadow, Peter M; Dahl, Douglas M; Feldman, Adam S; Arellano, Ronald S; Cornejo, Kristine M.
Affiliation
  • Valencia-Guerrero A; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Oliva E; Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
  • Wu CL; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Wu S; Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
  • Rice-Stitt T; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Sadow PM; Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
  • Dahl DM; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Feldman AS; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Arellano RS; Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
  • Cornejo KM; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Histopathology ; 78(7): 951-962, 2021 Jun.
Article in En | MEDLINE | ID: mdl-33236381
ABSTRACT

AIMS:

Perinephric fat invasion (PFI) is a key component of renal cell carcinoma (RCC) staging, but there are limited data pertaining to biopsy tract seeding (BTS) resulting in perirenal tissue involvement [BTS with perinephric fat invasion (BTS-P)].The aim is to correlate clinical outcomes with pathologic stage to determine whether the presence of BTS-P should be considered a criterion to stage RCC as part of the pT3a category in the absence of any other upstaging variables. MATERIALS AND

RESULTS:

We identified 304 renal biopsies from patients with subsequent nephrectomies for RCC; 33 of the tumours contained PFI. Each case was reviewed to determine the presence of BTS-P and other forms of invasion [e.g. non-BTS-P PFI, sinus fat invasion (SFI), and/or renal vein invasion (RVI)], and these findings were compared with survival outcomes. Ten (30%) of 33 tumours with PFI showed BTS-P as the only finding, and were otherwise pT1 tumours; six (60%) patients were alive without disease (AWOD) (mean, 77.5 months), three were lost to follow-up (LTF), and one died of other disease (DOOD). Two patients showed true PFI plus BTS-P; one was LTF and one is AWOD at 107 months. Ten (43%) of 23 patients with tumours with true invasion (PFI ± SFI and/or RVI) are AWOD (mean, 97.7 months), eight (35%) died of disease (DOD), four were LTF, and one DOOD. Kaplan-Meier survival curves showed that the cancer-specific survival was significantly worse in patients with true invasion (P = 0.044) than in those with BTS-P as the sole finding.

CONCLUSION:

Patients with tumours showing BTS-P only appear to have better outcomes than those with other non-PFI invasion, suggesting that this finding should not be upstaged to pT3a. Additional studies are needed to corroborate the significance of our observations.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prognosis / Carcinoma, Renal Cell / Neoplasm Staging Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Histopathology Year: 2021 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prognosis / Carcinoma, Renal Cell / Neoplasm Staging Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Histopathology Year: 2021 Document type: Article Affiliation country: United States